Antihistamines for allergic rhinitis - [Medication] - Quest Diagnostics Patient Health Library Topic Contents - Examples - How It Works - Why It Is Used - How Well It Works - Side Effects - What To Think About Antihistamines for allergic rhinitis - [Medication] - Quest Diagnostics Patient Health Library Antihistamines for allergic rhinitis - [Medication] - Quest Diagnostics Patient Health Library acrivastine, Alavert, Allegra, Allergic, allergic disorder, Allergies, Allergy,...
Teva Pharmaceutical Industries - News and PR - - Search Tevapharm: - - Press Release Teva Confirms Exercise of Option Under Collaboration with Impax Laboratories, Inc.Claritin ® D12), Loratadine/Pseudoephedrine Sulfate 24 hour Extended Release Tablets (generic of Claritin ® D24), ...
Paragraph IV Patent Certifications - DRUG NAME DOSAGE FORM STRENGTH RLD Acetaminophen Extended-release Tablets 650 mg Tylenol Acetaminophen/ Aspirin/ Caffeine Tablets 250 mg/250 mg/ 65 mg Excedrin (migraine) Acetaminophen and Tramadol Hydrochloride Tablets 325 mg/ 37.5 mg Ultracet Acyclovir Sodium1 Injection 50 mg/mL, 10 mL and 20 mL vials Zovirax Albuterol Sulfate Oral Syrup 2 mg(base)/ 5 mL Ventolin Albuterol...
http://www.fda.gov/cder/orange/appendix_a.txt 3, ACETAMINOPHEN ACETAMINOPHEN W/ CODEINE PHOSPHATE #3, ACETAMINOPHEN ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN ACETAMINOPHEN W/ CODEINE, ACETAMINOPHEN ACETAMINOPHEN, ACETAMINOPHEN (OTC) ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC) ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE, ACETAMINOPHEN ACETAMINOPHEN, BUTALBITAL AND CAFFEINE, ACETAMINOPHEN ACETAMINOPHEN,...
EFFICACY SUPPLEMENTS APPROVED IN CALENDAR YEAR 2003 FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER - Search - - EFFICACY SUPPLEMENTS APPROVED IN CALENDAR YEAR 2003 (SE1 -SE7)* and EFFICACY SUPPLEMENTS APPROVED IN CALENDAR YEAR 2003 (SE8)* - GENERIC NAME APPLICANT NDA NUMBER SUPP TYPE SUPP NUMBER RECEIPT DATE APPROVAL DATE PRIORITY REVIEW TOTAL APPROVAL TIME (MONTHS) INDICATION/DESCRIPTION FLUOXETINE...
CDER 2002 Report to the Nation; Drug Review continued Food and Drug Administration • Center for Drug Evaluation and Research About CDER - Report Search CDER Report to the Nation: 2002 Table of Contents Adobe Acrobat version of this document Drug Review (continued) Index Over-the-Counter Drug Review Generic Drug Review Assessing Data Quality, Research Risks User Fee Program Electronic Submissions Antimicrobial Resistance Pregnancy...
author: OLIVERN
Prescription and Over-the-Counter Drug Product List: 5/2003 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; BUTALBITAL; CAFFEINE TABLET; ORAL BUTALBITAL, APAP, AND CAFFEINE -A- AB AXIOM PHARM 325MG;50MG;40MG N89536 001 FEB 16, 1988 MAY CAHN -D- AB HALSEY 325MG;50MG;40MG N89536 001 FEB 16, 1988 MAY CAHN ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET; ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN -A- AA ABLE 500MG;7.5MG...
author: AUTHOR
Prescription and Over-the-Counter Drug Product List: 4/2003 45 -D- XCEL PHARMS 1MG/ML N05929 001 APR CFTG -A- AP + 1MG/ML N05929 001 APR CFTG -A- DIHYDROEROGTAMINE MESYLATE -A- AP PADDOCK 1MG/ML N40475 001 APR 28, 2003 APR NEWA DILTIAZEM HYDROCHLORIDE CAPSULE, EXTENDED RELEASE; ORAL -A- TAZTIA XT -A- AB4 ANDRX PHARMS 120MG N75401 001 APR 10, 2003 APR NEWA -A- AB4 180MG N75401 002 APR 10, 2003 APR NEWA -A- AB4 240MG N75401 003 APR 10, 2003 APR...
author: AUTHOR
First-Time Generics - February 2003 Food and Drug Administration • Center for Drug Evaluation and Research Drug Information Search First-Time Generics - February 2003 - Generic Drug Name Generic Manufacturer Brand Name- Approval Date 1 VINORELBINE TARTRATE INJECTION 10 MG (BASE)/ML; PACKAGED IN 10 MG/ML AND 50 MG/5 ML SINGLE-DOSE VIALS GENSIA SICOR PHARMACEUTICALS, INCLORATADINE ...
author: OGD
Prescription and Over-the-Counter Drug Product List: 3/2003 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE CAPSULE; ORAL FIORICET W/ CODEINE -D- AB + NOVARTIS 325MG;50MG;40MG;30MG N20232 001 JUL 30, 1992 MAR CAHN -A- AB + WATSON PHARMS 325MG;50MG;40MG;30MG N20232 001 JUL 30, 1992 MAR CAHN ACETAMINOPHEN; CODEINE PHOSPHATE TABLET; ORAL CODRIX -A- + ANDRX PHARMS 500MG;30MG N40441 001...
author: AUTHOR
19649873 claritin tsr insert Clinical trials of CLARITIN REDITABS (loratadine rapidly- disintegrating tablets) involved over 1300 patients who received either CLARITIN REDITABS (loratadine rapidly- disintegrating tablets), CLARITIN Tablets, or placeboCLARITIN REDITABS (loratadine rapidly- disintegrating tablets): Approximately 500 patients received CLARITIN ...
19649873 claritin tsr insert page 2
19649873 claritin tsr insert page 1
Efficacy Supplements Approved in Calendar Year 2002 (SE1-SE7 AND SE8s LORATADINE SCHERING 19-658 SE6 018 28-Jan-02 27-Nov-02 - 10.0 Provides for the over-the-counter use of Claritin (loratadine) Tablets for the temporary relief of symptoms of hay fever or other upper respiratory allergies: runny nose, sneezing, itchy, watery eyes, and itching of the nose or throatLORATADINE SCHERING 20-704 SE6 008 28-Jan-02 27-Nov-02 - 10.0...
author: Darlene Norris
News & PR - TEVA Pharmaceutical Industries Ltd TEVA CONFIRMS EXERCISE OF OPTION UNDER COLLABORATION WITH IMPAX LABORATORIES, INCClaritin ® D12), Loratadine/Pseudoephedrine Sulfate 24 hour Extended Release Tablets (generic of Claritin ® D24), Loratadine Orally Disintegrating...
CLARITIN Clinical trials of CLARITIN REDITABS (loratadine rapidly- disintegrating tablets) involved over 1300 patients who received either CLARITIN REDITABS (loratadine rapidly- disintegrating tablets), CLARITIN Tablets, or placeboCLARITIN REDITABS (loratadine rapidly- disintegrating tablets): Approximately 500 patients received CLARITIN ...
author: JGRACE
subject: LABELING
CLARITIN page 2
author: JGRACE
subject: LABELING
CLARITIN page 1
author: JGRACE
subject: LABELING
What's new at CDER by Date - U.S
author: Paul Stauffer
FDA Drug Approvals List June 2002 - Drug Approvals for June 2002 Definitions and Notes Original New Drug Applications Original Application # 021316 Approval Date: 26-JUN-02 Trade Name: ALTOCOR Chemical Type: 3 Therapeutic Potential: S Dosage Form: TABLET Applicant: AURA LABORATORIES INC Active Ingredient(s): LOVASTATIN OTC/RX Status: RX INDICATION OF USE: For lowering total cholesterol and LDL-C to target levels as...
The Growing Pediatrics Market FOR GLOBAL BUSINESS AND MARKETING LEADERS page 3
author: DAVID BERGSTROM, EUGENE MCNALLY, AND STEVE FREEMAN
http://www.tevapharm.com/pdf/20-F_20040315.pdf UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
http://www.tevapharm.com/pdf/20-F_20040315.pdf page 20
Previous News Items 2002 Food and Drug Administration • Center for Drug Evaluation and Research Center for Drug Evaluation and Research Search Previous News Items 2002 Previous News Items 2003 December 20, 2002 FDA approves Gleevec (imatinib mesylate) for the first-line treatment of patients with chronic myeloid leukemia (CML), an uncommon life-threatening form of cancer affecting about 40,000 people in...
author: DLIS
http://www.fda.gov/cder/foi/appletter/2003/19658se6-020,20704se6-009,20641se6-011ltr.pdf page 1
author: ABRAHAM
